Pilot evaluation of aprepitant for the treatment of hot flashes

Supportive Cancer Therapy

Volumn 3, Issue 4, 2006, Pages 240-246

  Bardia, Aditya ^b   Thompson, Susan ^b   Atherton, Pamela J ^b   Barton, Debra L ^b   Sloan, Jeff A ^b   Kottschade, Lisa A ^b   Christensen, Brad ^b   Collins, Mary ^c   Loprinzi, Charles L ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c Carle Clinic   (United States)

Author keywords

Gabapentin; Hormone replacement therapy; Neurokinin receptors; Neurotransmitters; Tamoxifen

Indexed keywords

APREPITANT; GABAPENTIN; PAROXETINE; VENLAFAXINE;

ADULT; ANOREXIA; ANXIETY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HICCUP; HOT FLUSH; HUMAN; MORBIDITY; MORTALITY; NERVOUSNESS; ORGASM DISORDER; QUALITY OF LIFE; RASH; SIDE EFFECT; SLEEP DISORDER; SWEATING; TENSION; VAGINA PAIN; VOMITING;

EID: 33749503437     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.022     Document Type: Conference Paper

References (52)

1. Gracia CR, Freeman EW. Acute consequences of the menopausal transition: the rise of common menopausal symptoms. Endocrinol Metab Clin North Am 2004; 33:675-689.
2. Carpenter JS. The hot flash related daily interference scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001; 22:979-989.
3. Finck G, Barton DL, Loprinzi CL, et al. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998; 16:327-333.
4. Greendale G, Lee N, Arriola E. The menopause. Lancet 1999; 353:571-580.
5. Loprinzi CL, Zahasky KM, Sloan JA, et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000; 1:52-56.
6. Stein KD, Jacobsen PB, Hann DM, et al. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 2000; 19:436-445.
7. Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors Breast J 2003; 9:431-438.
8. Carpenter J, Adrykowski M, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma. Cancer 1998; 82:1682-1691.
9. Carpenter JS, Johnson D, Wagner L, et al. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002; 29:E16-E25.
10. Moorhead T, Hannaford P, Warskyj M. Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br J Obstet Gynaecol 1997; 104:290-297.
11. Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance. Obstet Gynecol 1997; 90:269-277.
12. Nand SL, Webster MA, Baber R, et al. Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Climacteric 1998; 1:211-218.
13. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347-352.
14. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obst Gynecol 1998; 92:982-988.
15. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
16. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92:328-332.
17. Porch JV, Lee IM, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Cause Control 2002; 13:847-854.
18. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer [published erratum in JAMA 1991; 266:1362]. JAMA 1991; 265:1985-1990.
19. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast canter in postmenopausal women. N Engl J Med 1995; 332:1589-1593.
20. Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321:293-297.
21. Collaborative Group on Hormonal factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350:1047-1059.
22. Consensus Statement. Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. J Clin Endocrinol Metab 1998; 83:1993-2000. Review.
23. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004; 292:1983-1988.
24. Shanafelt TD, Barton DL, Adjei AA, et al. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77:1207-1218. Review.
25. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized phase III controlled trial ot venlafaxine in the management of hot flashes. Lancet 2000; 356:2059-2063.
26. Evans ML, Pritts E, Vittinghoff E, et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005; 105:161-166.
27. Stearns V, Isaacs C, Crawford J. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil™) in controlling hot flashes. Breast Cancer Res Treat 1997; 1:308 (Abstract #452).
28. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289:2827-2834.
29. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005; 23:6919-6930.
30. Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of epomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol 2006; 24:1409-1414.
31. Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Glynecol 2000; 95:726-731.
32. Guttuso TJ Jr. Gabapenrin's effects on hot flashes and hypothermia. Neurology 2000; 54:2161-2163.
33. Loprinzi CL, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77:1159-1163.
34. Pandya KJ, Thummala AR, Griggs JJ, et al. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat 2004; 83:87-89.
35. Guttuso T Jr, Kurlan R, McDermott MP, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101:337-345.
36. Guttuso TJ, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003; 361:1703-1705.
37. Mantyh PW, Hunt SP, Maggio JE. Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res 1984; 307:147-165.
38. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for anti-depressant activity by blockade of central substance P receptors. Science 1998; 281:1640-1645.
39. US Food and Drug Administration Emend Consumer Drug Information Sheet. Available at: http://www.fda.gov/cder/consumerinfo/druginfo/emend.htm. Accessed November 23, 2005.
40. Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41:1278-1285.
41. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and rolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822-2830.
42. Rupniak NM, Kramer MS. Discovery of the antidepressant and antiemeric efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20:485-490.
43. Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29:385-392.
44. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003; 1:47-51.
45. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16:495-500.
46. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16:277-2381.
47. Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001; 19:4280-1290.
48. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-651
49. MacGregor CA, Canney PA, Patterson G, et al. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. Eur J Cancer 2005; 41:708-714.
50. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) study: a randomized controlled trial. JAMA 2003; 290:207-214.
51. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: an NCCTG trial. J Clin Oncol 2000; 18:1068-1074.
52. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36:155-164.